Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | MGAM | O43451 | 1/20 | 0.58 |
| ▸ | SI | P14410 | 1/20 | 0.58 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.58 |
| ▸ | PAM | P19021 | 2/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.48 |
| ▸ | PPARG | P37231 | 7/20 | 0.48 |
| ▸ | PPARD | Q03181 | 7/20 | 0.48 |
| ▸ | PPARA | Q07869 | 7/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | FABP4 | P15090 | 2/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexane SCHEMBL2556421 | 0.98 | MGAM (0.61) | GAAMGAMSIMGAM2PAM | |
| Pentane SCHEMBL11290040 | 0.93 | GAA (0.61) | GAAMGAMSIMGAM2PAM | |
| Butane SCHEMBL4659711 | 0.89 | GAA (0.67) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL15376 | 0.89 | — | — | |
| SCHEMBL30741390 | 0.89 | GAA (0.74) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL27351378 | 0.88 | MGAM (0.50) | GAAMGAMSIMGAM2PAM | |
| Water SCHEMBL2811574 | 0.86 | GAA (0.70) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL3201235 | 0.86 | GAA (0.70) | GAAMGAMSIMGAM2TSHR | |
| SCHEMBL13278763 | 0.86 | GAA (0.70) | GAAMGAMSIMGAM2TSHR | |
| Hydrochloric Acid SCHEMBL356491 | 0.86 | GAA (0.70) | GAAMGAMSIMGAM2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619182-B1 | PHARMACEUTICAL COMPOSITION | EISAI R&D MAN CO LTD (JP) | 2016-11-09 | — | — | EP | disclosed |
| EP-3061751-A1 | PHARMACEUTICAL COMPOSITION | Eisai R&D Management Co., Ltd. (JP) | 2016-08-31 | — | — | EP | disclosed |
| CN-103097358-B | Pharmaceutical composition | EISAI R&D MAN CO LTD | 2015-04-08 | — | — | CN | disclosed |
| US-9000024-B2 | Pharmaceutical composition | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-07 | — | — | US | disclosed |
| CN-102405211-B | Proline derivatives as cathepsin inhibitors | HOFFMANN LA ROCHE | 2015-01-21 | — | — | CN | disclosed |
| US-20140155452-A1 | PHARMACEUTICAL COMPOSITION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-05 | — | — | US | disclosed |
| EP-2421826-B1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20130237578-A1 | PHARMACEUTICAL COMPOSITION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-09-12 | — | — | US | disclosed |
| EP-2619182-A1 | PHARMACEUTICAL COMPOSITION | Eisai R&D Management Co., Ltd. (JP) | 2013-07-31 | — | — | EP | disclosed |
| CN-103097358-A | Pharmaceutical composition | EISAI R&D MAN CO LTD | 2013-05-08 | — | — | CN | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| WO-2012039972-A1 | PHARMACEUTICAL COMPOSITION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-03-29 | — | — | WO | disclosed |
| EP-2421826-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010121918-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | PRAP1, PRR12, SLC6A7 | GAA 2111/4885MGAM 4471/4885SI 2728/4885 |
| US-20140155452-A1 | PHARMACEUTICAL COMPOSITION | CYP3A5, CYP2C19, CYP3A7 | GAA 255/4885MGAM 1475/4885SI 337/4885 |
| US-20130237578-A1 | PHARMACEUTICAL COMPOSITION | CYP3A5, CYP2C19, CYP3A7 | GAA 255/4885MGAM 1475/4885SI 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.